Enanta Pharmaceuticals Inc
ENTA
Market Cap$126.93M
Close$
$-7.91
248.6% downside
Current Fair Value
248.6% downsideOvervalued by 248.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $126.93 Million |
|---|---|
| Enterprise Value | $100.04 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-5.48 |
| Beta | 0.7 |
| Outstanding Shares | 21,238,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.2 |
|---|---|
| PEG | -47.28 |
| Price to Sales | 1.77 |
| Price to Book Ratio | 1.06 |
| Enterprise Value to Revenue | 1.48 |
| Enterprise Value to EBIT | -0.87 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.57 |
| Debt to Equity | 0.51 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Enanta Pharmaceuticals Inc
CEO: Jay Luly